BioNTech Stock Will Soar With Its First-Mover Vaccine Advantage

٤ سبتمبر ٢٠٢٠

BNTX a German company and its american partner PFE
will likely have a first-mover advantage in the coronavirus vaccine race in the U.S. This will affect both stocks, once the final vaccine results are in.

Assuming the bottom is in and we are about to continue the Trend as previously, im expecting a big move after the approval, so dont forget to take risk of the table!

The reason for this is that the two companies are expecting to be the first to produce large-scale results from their Phase 2/3 clinical trials in October, according to Barron’s.
Depending on how effective their vaccine is, the U.S. Food and Drug Administration may even grant it emergency-use authorization

The advantage of their trial is that it is large, involving more than 30,000 participants.
The FDA wants to see at least 50% efficacy in trials before granting any Covid-19 authorization.

Why BioNTechs Vaccine Looks Like a Winner

With Pfizer in the back FDA and President Donald Trump are likely to move quickly.
According to them even the first small study with 24 Persons that took their messenger RNA vaccine produced antibodies.
With a lower doses usage of the vaccine and developed antibodies after 28 days — at levels about two times higher than in normal, recovering Covid-19 patients.

BioNTech and Fosun Pharma to Potentially Supply 10 Million Doses of BioNTech’s BNT162 to Hong Kong SAR and Macao SAR
Also a Deal to Supply Japan with 120 Million Doses of Their BNT162 mRNA-Based Vaccine Candidat

This combined with the huge buying volume and market shifts will grant momentum for bigger goals.

Just think about what ccould happen when they get kinda a monopol situation going for them.

Thank you for take the time and reading this and as always stay storng in those shaky times!

Sebastian